Revance Therapeutics (RVNC) Projected to Post Earnings on Wednesday

Revance Therapeutics (NASDAQ:RVNC) is projected to post its quarterly earnings results before the market opens on Wednesday, February 26th. Analysts expect Revance Therapeutics to post earnings of ($0.29) per share and revenue of $78.12 million for the quarter.

Revance Therapeutics Stock Performance

Shares of RVNC opened at $3.65 on Tuesday. The company has a 50-day simple moving average of $3.42 and a 200-day simple moving average of $4.60. Revance Therapeutics has a 52 week low of $2.30 and a 52 week high of $7.56. The firm has a market capitalization of $381.02 million, a P/E ratio of -1.89 and a beta of 0.90.

Analyst Ratings Changes

Several equities analysts have commented on RVNC shares. Barclays cut their price target on Revance Therapeutics from $7.00 to $3.00 and set an “equal weight” rating for the company in a report on Monday, December 23rd. StockNews.com started coverage on Revance Therapeutics in a research note on Saturday. They issued a “hold” rating for the company. HC Wainwright reiterated a “neutral” rating and set a $6.60 price target on shares of Revance Therapeutics in a research note on Friday, November 8th. Mizuho dropped their price objective on shares of Revance Therapeutics from $6.66 to $3.10 and set a “neutral” rating for the company in a research note on Tuesday, December 10th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Revance Therapeutics in a report on Friday, January 17th. Nine research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. According to data from MarketBeat, Revance Therapeutics has a consensus rating of “Hold” and an average price target of $8.39.

About Revance Therapeutics

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.